Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

M, Ando; I, Okamoto; N, Yamamoto; K, Takeda; K, Tamura; T, Seto; Y, Ariyoshi; M, Fukuoka

doi:10.1200/jco.2005.04.9866

Public

Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

Shared by NobleBlocks on Jun 1, 2006 • 12:00 AM UTC

Authors:

Ando M

Okamoto I

Yamamoto N

Abstract

<h4>Purpose</h4>Interstitial lung disease (ILD) is a serious adverse effect of gefitinib, but its prevalence and risk factors remain largely unknown. We examined the prevalence of and risk factors for gefitinib-induced ILD associated with practical use of the drug in Japanese with non-small-cell lun...

Discussions